Give me high-yield HKMLE notes on Respiratory Pharmacology with mnemonics, in an easy-to-read format. Include only what is necessary for HKMLE. Do not add extra details unless they are clinically important for the exam. Keep it very short — 2-3 pages maximum. For each drug or drug class, tell me: 1. Mechanism (simple) 2. Key indications (HKMLE-relevant) 3. Major side effects (exam-tested) 4. Contraindications (if any) 5. Where this topic appears in HKMLE (Paper I, II, or III) Use tables where helpful. No long paragraphs. No fluff.
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
I now have enough material from the textbooks to compile comprehensive, exam-focused notes. Let me write these up.
HKMLE High-Yield Notes: Respiratory Pharmacology
MNEMONIC OVERVIEW: "BAMS-LO-CT"
Beta-2 agonists | Anticholinergics | Mast cell stabilisers | Steroids (inhaled) | Leukotriene modifiers | Omalizumab/Biologics | Chromones | Theophylline
1. BETA-2 AGONISTS
SABA (Short-Acting): Salbutamol (Albuterol), Terbutaline
LABA (Long-Acting): Salmeterol, Formoterol
Mnemonic: "SALt Saves Asthma" (Salbutamol = first-line rescue)
| Feature | SABA | LABA |
|---|---|---|
| Mechanism | Beta-2 receptor agonist → adenylyl cyclase → cAMP ↑ → smooth muscle relaxation (bronchodilation) | Same mechanism, longer duration |
| Indication | Acute asthma attack (rescue), step 1 PRN | Step 3+ add-on to ICS; NOT monotherapy |
| Onset | Minutes | ~30 min (salmeterol), minutes (formoterol) |
| Duration | 4-6 h | 12 h |
| Key SE | Tremor, tachycardia, hypokalaemia, hyperglycaemia | Same + risk of asthma death if used without ICS |
| Contraindication | LABA monotherapy in asthma (black box) | - |
HKMLE Paper: Paper I (Pharmacology MCQ), Paper III (Clinical management)
Exam trap: Salbutamol causes hypokalaemia (beta-2 shifts K+ into cells). Salmeterol must NEVER be used without ICS.
2. ANTICHOLINERGICS (SAMA / LAMA)
Mnemonic: "I TAME COPD" (Ipratropium = SAMA; Tiotropium = LAMA)
| Feature | Ipratropium (SAMA) | Tiotropium (LAMA) |
|---|---|---|
| Mechanism | M3 receptor antagonist → blocks bronchoconstriction | Same, higher affinity, longer-acting |
| Indication | Acute COPD exacerbation; adjunct in acute severe asthma ER | COPD maintenance (1st line); add-on in severe asthma |
| Dosing | QID inhaler | Once daily |
| Key SE | Dry mouth, urinary retention, constipation, blurred vision | Same (systemic effects minimal due to poor GI absorption) |
| Contraindication | Caution in BPH, narrow-angle glaucoma | Same |
HKMLE Paper: Paper I (Pharmacology), Paper III (COPD management)
These are quaternary ammonium compounds - they do NOT cross the BBB, hence minimal CNS effects.
3. INHALED CORTICOSTEROIDS (ICS)
Drugs: Beclomethasone, Budesonide, Fluticasone, Mometasone
Mnemonic: "BuFlo Blocks Inflammation" (Budesonide, Fluticasone = most commonly tested)
| Feature | Details |
|---|---|
| Mechanism | Bind glucocorticoid receptor → reduce eosinophilic inflammation, decrease mucus production |
| Indications | Persistent asthma (step 2+); COPD with frequent exacerbations |
| Local SE | Oral candidiasis, dysphonia (hoarseness) |
| Systemic SE | Minimal at low doses; high dose → adrenal suppression, growth retardation in children, cataracts, osteoporosis |
| Contraindication | None absolute; caution in active pulmonary TB |
| Prevention of SE | Rinse mouth after use (candidiasis), spacer device |
HKMLE Paper: Paper I, Paper III
Exam trap: ICS do NOT cause systemic Cushing's at standard doses. Growth suppression is tested in paediatric questions.
4. THEOPHYLLINE
Mnemonic: "THEOPHYLLINE = Toxic drug with Narrow window, SeizureRisk, Arrhythmia"
| Feature | Details |
|---|---|
| Mechanism | PDE inhibitor → cAMP ↑ → bronchodilation; also adenosine receptor antagonist |
| Indications | Chronic asthma/COPD (3rd line, now rarely used); acute severe asthma (IV aminophylline) |
| Therapeutic range | 10-20 mg/L (narrow therapeutic index) |
| Toxic SE (>20 mg/L) | Seizures, ventricular arrhythmias, nausea/vomiting, tachycardia |
| Drug interactions | Ciprofloxacin, erythromycin, cimetidine → increase levels (CYP1A2 inhibitors). Rifampicin, smoking → decrease levels |
| Contraindication | Epilepsy, cardiac arrhythmias |
HKMLE Paper: Paper I (heavy - drug interactions, toxicity), Paper II (toxicology)
Exam trap: Theophylline toxicity symptoms - "TANS": Tachycardia, Arrhythmia, Nausea, Seizures.
5. LEUKOTRIENE RECEPTOR ANTAGONISTS (LTRA)
Drug: Montelukast, Zafirlukast
Mnemonic: "MonteluKAST Blocks Inflammation After ASThma and Allergies"
| Feature | Details |
|---|---|
| Mechanism | Block CysLT1 receptors → reduce bronchoconstriction, mucus secretion, eosinophil recruitment |
| Indications | Mild persistent asthma (alternative or add-on to ICS); allergic rhinitis; aspirin-exacerbated respiratory disease (AERD); exercise-induced bronchospasm |
| Key SE | Generally well-tolerated; neuropsychiatric effects (depression, suicidality - FDA warning); Churg-Strauss vasculitis (rare, on steroid taper) |
| Advantage | Oral; good for aspirin-sensitive asthma |
| Contraindication | History of psychiatric illness (relative) |
HKMLE Paper: Paper I, Paper III
Exam trap: LTRA are the drug of choice in aspirin-induced asthma / NSAID-sensitive asthma.
6. MAST CELL STABILISERS
Drugs: Sodium cromoglicate (cromolyn), Nedocromil
| Feature | Details |
|---|---|
| Mechanism | Inhibit mast cell degranulation → block release of histamine, leukotrienes |
| Indications | Prophylaxis of mild asthma (especially exercise-induced or allergen-induced); allergic rhinitis |
| Key SE | Minimal; cough/throat irritation on inhalation |
| Contraindication | Not for acute attacks (prophylaxis only) |
| Limitation | Less effective than ICS; now rarely used |
HKMLE Paper: Paper I
7. BIOLOGICS (Anti-IgE / Anti-IL-5 / Anti-IL-4)
Mnemonic: "OMG, More Exacerbations Drop: Omalizumab, Mepolizumab, Dupilumab"
| Drug | Target | Indication | Key SE |
|---|---|---|---|
| Omalizumab | Anti-IgE | Severe allergic asthma (high IgE, sensitised) | Anaphylaxis (must observe post-injection), injection site reactions |
| Mepolizumab / Benralizumab / Reslizumab | Anti-IL-5 (↓eosinophils) | Severe eosinophilic asthma | Injection site reactions, headache |
| Dupilumab | Anti-IL-4/IL-13 | Severe type-2 asthma, also atopic dermatitis, nasal polyps | Injection site, eosinophilia (transient) |
HKMLE Paper: Paper III (newer guidelines questions); Paper I (mechanism MCQs)
QUICK COMPARISON: ASTHMA vs COPD Drug Preference
| Drug Class | Asthma | COPD |
|---|---|---|
| SABA | First-line rescue | Rescue (adjunct) |
| LABA | Must add with ICS | 1st/2nd line maintenance |
| LAMA | Add-on (severe asthma) | 1st line maintenance |
| ICS | Cornerstone treatment | Only if frequent exacerbations |
| Theophylline | 3rd line | 3rd line |
| LTRA | Add-on / aspirin asthma | Not indicated |
HKMLE EXAM TRAPS SUMMARY
| Trap | Answer |
|---|---|
| Hypokalaemia from salbutamol | Beta-2 shifts K+ intracellularly |
| LABA without ICS in asthma | Contraindicated - increases asthma death |
| Drug of choice: aspirin-sensitive asthma | LTRA (montelukast) |
| Theophylline toxicity signs | Seizure, arrhythmia, nausea |
| Ciprofloxacin + theophylline | Toxicity (CYP1A2 inhibition) |
| ICS side effect to prevent by rinsing mouth | Oral candidiasis |
| Tiotropium vs Ipratropium | Tiotropium = LAMA (once daily, COPD maintenance) |
| Omalizumab use requires | Elevated serum IgE + allergen sensitisation |
| Montelukast CNS warning | Depression / suicidal ideation |
| LABA in COPD | Can use alone (unlike asthma) |
Paper allocation summary:
- Paper I (Basic sciences/Pharmacology): Mechanism, drug interactions, theophylline toxicity, ICS side effects
- Paper II (Clinical sciences): Drug toxicology, prescribing in pregnancy
- Paper III (Clinical management): Step-up therapy, COPD vs asthma management, biologics selection
Give me high-yield HKMLE notes on Respiratory Pharmacology with mnemonics, in an easy-to-read format. Include only what is necessary for HKMLE. Do not add extra details unless they are clinically important for the exam. For each drug or drug class, tell me: 1. Mechanism (simple) 2. Key indications (HKMLE-relevant) 3. Major side effects (exam-tested) 4. Contraindications (if any) 5. Where this topic appears in HKMLE (Paper I, II, or III) Use tables where helpful. No long paragraphs. No fluff.
Here are your high-yield HKMLE Respiratory Pharmacology notes, compiled from Katzung, Lippincott, Goodman & Gilman, and Murray & Nadel:
HKMLE High-Yield: Respiratory Pharmacology
Master mnemonic: "BALTICS"
Beta-2 agonists | Anticholinergics | Leukotriene modifiers | Theophylline | ICS | Chromones | Steroids (systemic) + biologics
1. BETA-2 AGONISTS
SABA - Salbutamol (albuterol), Terbutaline
LABA - Salmeterol, Formoterol
| SABA | LABA | |
|---|---|---|
| Mechanism | Beta-2 agonist → cAMP ↑ → airway smooth muscle relaxation | Same, longer duration |
| Indication | Acute asthma rescue; acute COPD exacerbation | Step 3+ asthma (with ICS); COPD maintenance |
| SE | Tremor, tachycardia, hypokalaemia, hyperglycaemia | Same + asthma death risk if used without ICS |
| CI | None absolute | Monotherapy in asthma (black box) |
Paper: I (mechanism, SE), III (step therapy)
Trap 1: Salbutamol → hypokalaemia (beta-2 drives K+ into cells). Tested in overdose/ICU scenarios. Trap 2: LABA alone in asthma = contraindicated. Must always combine with ICS. Formoterol has fast onset (can double as rescue); salmeterol does not.
2. ANTICHOLINERGICS (SAMA / LAMA)
Mnemonic: "I'm SAMA, Tio's LAMA" (Ipratropium = SAMA; Tiotropium = LAMA)
| Ipratropium (SAMA) | Tiotropium (LAMA) | |
|---|---|---|
| Mechanism | M3 antagonist → blocks bronchoconstriction | Same, higher affinity, once-daily |
| Indication | Acute severe asthma (ER add-on to SABA); COPD exacerbation | COPD maintenance (1st line); add-on in severe asthma |
| SE | Dry mouth, urinary retention, blurred vision, constipation | Same (minimal systemic - quaternary compound, poor absorption) |
| CI | Narrow-angle glaucoma, BPH (relative) | Same |
Paper: I (mechanism), III (COPD management)
Trap: Quaternary ammonium structure = does NOT cross BBB = no CNS effects. These are inhaled only. Tiotropium in COPD reduces exacerbations and improves exercise tolerance.
3. INHALED CORTICOSTEROIDS (ICS)
Drugs: Beclomethasone, Budesonide, Fluticasone, Mometasone
Mnemonic: "Rinse or you'll get Thrush" - rinse mouth after every dose
| Feature | Details |
|---|---|
| Mechanism | Glucocorticoid receptor activation → suppress eosinophilic airway inflammation |
| Indication | Persistent asthma (step 2 onward); COPD with recurrent exacerbations (combined with LABA) |
| Local SE | Oral candidiasis, dysphonia (hoarseness) |
| Systemic SE | Rare at low dose; high dose → adrenal suppression, growth retardation (children), osteoporosis, cataracts |
| Prevention | Rinse mouth after use; use spacer |
| CI | No absolute CI; caution in active TB |
Paper: I (SE, mechanism), III (step-up therapy, paediatric asthma)
Trap: ICS do NOT cause systemic Cushing's at standard doses. Growth suppression is the paediatric exam question.
4. THEOPHYLLINE
Mnemonic: "TANS" = Theophylline toxicity: Tachycardia, Arrhythmia, Nausea, Seizures
| Feature | Details |
|---|---|
| Mechanism | PDE inhibitor → cAMP ↑ → bronchodilation; also adenosine receptor antagonist |
| Indication | Chronic asthma/COPD (3rd line); IV aminophylline for acute severe asthma |
| Therapeutic range | 10-20 mg/L (narrow therapeutic index) |
| Toxic SE (>20 mg/L) | Seizures, ventricular arrhythmias, N&V, tachycardia |
| CI | Epilepsy, cardiac arrhythmias |
Drug interactions (very heavily tested):
| Increases theophylline levels (toxicity risk) | Decreases theophylline levels |
|---|---|
| Ciprofloxacin, Erythromycin, Cimetidine (CYP1A2 inhibitors) | Rifampicin, Phenytoin, Smoking (CYP1A2 inducers) |
Paper: I (interactions, toxicity - high yield), II (toxicology/prescribing)
Trap: Patient on theophylline starts ciprofloxacin for chest infection → theophylline toxicity. Classic HKMLE scenario.
5. LEUKOTRIENE MODIFIERS
Drug: Montelukast (LTRA), Zafirlukast (LTRA), Zileuton (5-LOX inhibitor)
Mnemonic: "Montelukast for Aspirin Asthma & Allergic Athletes"
| Feature | Details |
|---|---|
| Mechanism | Block CysLT1 receptors → reduce bronchoconstriction + eosinophil recruitment |
| Indication | Mild persistent asthma (add-on or ICS alternative); aspirin/NSAID-exacerbated asthma; allergic rhinitis; exercise-induced bronchospasm |
| SE | Neuropsychiatric effects (depression, suicidality - FDA black box); Churg-Strauss vasculitis (rare, on steroid taper) |
| Advantage | Oral; useful in aspirin-sensitive asthma |
| CI | Caution with psychiatric history |
Paper: I, III
Trap 1: Drug of choice for aspirin-sensitive (AERD) asthma = LTRA. Very high-yield. Trap 2: Churg-Strauss association - eosinophilic vasculitis appearing when oral steroids are tapered.
6. MAST CELL STABILISERS
Drugs: Sodium cromoglicate (cromolyn), Nedocromil
| Feature | Details |
|---|---|
| Mechanism | Inhibit mast cell degranulation → block histamine + leukotriene release |
| Indication | Prophylaxis: mild asthma, exercise-induced bronchospasm, allergic rhinitis |
| SE | Minimal; cough/throat irritation |
| CI | NOT for acute attacks - prophylaxis only |
Paper: I
These are now rarely used in practice but appear in mechanism-type Paper I MCQs.
7. BIOLOGICS
Mnemonic: "O-M-D targets IgE, IL-5, IL-4" (Omalizumab, Mepolizumab, Dupilumab)
| Drug | Target | Indication | Key SE |
|---|---|---|---|
| Omalizumab | Anti-IgE | Severe allergic asthma (elevated IgE, allergen sensitised) | Anaphylaxis (30-min observation required), injection site reactions |
| Mepolizumab / Benralizumab | Anti-IL-5 (↓ eosinophils) | Severe eosinophilic asthma | Injection site reactions |
| Dupilumab | Anti-IL-4/IL-13 | Severe type-2 asthma; also atopic dermatitis + nasal polyps | Injection site; transient eosinophilia |
Paper: I (mechanism), III (patient selection)
Omalizumab prerequisite: elevated serum IgE AND documented allergen sensitisation.
ASTHMA vs COPD: Drug of Choice Summary
| Drug Class | Asthma | COPD |
|---|---|---|
| SABA | 1st-line rescue | Rescue (as needed) |
| LABA | Add-on to ICS only | 1st-line maintenance (can use alone) |
| LAMA (Tiotropium) | Add-on in severe/uncontrolled | 1st-line maintenance (preferred) |
| ICS | Cornerstone (step 2+) | Only if frequent exacerbations |
| Theophylline | 3rd line | 3rd line |
| LTRA | Add-on / aspirin asthma | Not indicated |
| Biologics | Severe uncontrolled | Not indicated |
TOP EXAM TRAPS AT A GLANCE
| Scenario | Answer |
|---|---|
| Salbutamol overdose → low K+ | Beta-2 agonist shifts K+ intracellularly |
| LABA without ICS in asthma | Contraindicated - increases asthma mortality |
| Aspirin-sensitive asthma drug | Montelukast (LTRA) |
| Theophylline + ciprofloxacin | Toxicity (CYP1A2 inhibition ↑ theophylline levels) |
| Theophylline + rifampicin/smoking | Sub-therapeutic levels (CYP1A2 induction) |
| ICS side effect prevented by rinsing mouth | Oral candidiasis |
| Tiotropium vs Ipratropium | Tiotropium = LAMA, once daily, COPD maintenance |
| Omalizumab requirement | High IgE + allergen sensitisation |
| Montelukast CNS warning | Depression / suicidal ideation |
| LABA monotherapy: OK in COPD? | Yes. OK in COPD, NOT in asthma |
Take my existing HKMLE Respiratory Pharmacology notes (attached as Resp 💊.pdf) and improve them as follows: 1. Keep ALL existing content exactly as is — do not delete anything. 2. Add the following three missing sections in the same style (tables, mnemonics, HKMLE pearls): **Section A: TB Drugs (RIPE)** - One table with: Drug | Mechanism (1 line) | Unique Toxicity | HKMLE Pearl - Include mnemonic: "RIP PE" (Rifampicin-orange, INH-neuropathy, Pyrazinamide-urate, Ethambutol-eyes) - Paper mapping: Paper I (Medicine MCQs), Paper II (emergency if on TB drugs) **Section B: Pneumonia Antibiotics (CAP vs HAP)** - One table with: Setting | First-line | Alternative - Settings: CAP outpatient, CAP inpatient, HAP (non-severe) - Add 1 HKMLE pearl below table **Section C: Inhaler Devices** - One table with: Device | When to use | Key point (1 line each) - Devices: MDI, DPI, Spacer 3. Add a "Quick Mnemonics Cheat Sheet" at the end (like your Cardio notes have) with all respiratory mnemonics from the document. 4. Add a "HKMLE Paper Distribution Summary" table (like Cardio notes) showing which respiratory topics appear in which paper. 5. Fix any formatting issues (broken tables, missing lines). 6. Match the EXACT style of your Cardio 💊.pdf — same table formatting, same use of "HKMLE Pearl", same mnemonic style. Output the complete, improved Respiratory notes as a single document.
Reading File
Running Command
Reading File
Running Command
Running Command
Writing File
Running Command
This is a shared conversation. Sign in to Orris to start your own chat.